InvestorsHub Logo
Followers 41
Posts 4235
Boards Moderated 0
Alias Born 08/01/2007

Re: None

Tuesday, 12/22/2009 4:18:14 PM

Tuesday, December 22, 2009 4:18:14 PM

Post# of 146240
VICL patents HSV vaccine.

"...announced today the issuance of U.S. Patent No. 7,628,993 covering DNA vaccines for herpes simplex virus type 2 (HSV-2). HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. Vical is collaborating under a previously disclosed grant on the preclinical development of an HSV-2 vaccine which will be designed for use in people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups and the associated viral shedding and transmission. The vaccine will be evaluated with Vical's Vaxfectin adjuvant."

This is from a news streamer so I don't have a link
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News